The effect of $\beta_2$-adrenoceptor agonists and steroids on induced airway inflammation and bronchial responsiveness

AKADEMIK AVHANDLING
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras på svenska språket i Hillarpsalen, Retzius väg 8, Karolinska Institutet

Fredagen den 12 juni 2009 kl. 09.00

av

Karin Strandberg
Leg. läkare

Huvudhandledare:
Professor Kjell Larsson
Karolinska Institutet
Institutet för Miljömedicin

Bihandledare:
Docent Lena Palmberg
Karolinska Institutet
Institutet för Miljömedicin

Fakultetsopponent:
Professor Thomas Sandström
Umeå Universitet
Institutionen för Folkhälsa och klinisk medicin

Betygsnämnd:
Professor Jon Lundberg
Karolinska Institutet
Institutionen för Fysiologi och Farmakologi

Docent Reidar Grönneberg
Karolinska Universitetssjukhuset
Lung- och Allergikliniken

Docent Gunnemar Ståhlenheim
Uppsala Universitet
Institutionen för medicinska vetenskaper,
Lungmedicin och Allergologi

Stockholm 2009
Abstract

Acute exposure of healthy subjects in a swine barn induces an intense airway inflammation and increased bronchial responsiveness. Dust collected in swine houses is a potent stimulus for release of pro-inflammatory cytokines from cells in vitro. The main aim of this thesis was to elucidate the effects of long-acting $\beta_2$-agonists and glucocorticosteroids on inflammatory mechanisms in vivo and in vitro using organic dust as pro-inflammatory stimulus.

In the first study, formoterol and salmeterol were shown to induce enhancement of IL-6 and IL-8 release from non-stimulated primary bronchial epithelial cells (PBEC) and A549 cells in vitro. The $\beta_2$-agonists also added to the effect of organic dust. This enhanced release was blocked by a $\beta$-blocker in PBEC, but not in A549 cells. The results indicate different mechanisms of $\beta_2$-agonists action in bronchial and alveolar epithelial cells, and that A549 cells do not possess functional $\beta_2$-adrenoceptors.

In the second study, formoterol was shown to add to the dust-induced IL-6, but not IL-8 release from PBEC. Budesonide attenuated the release of both cytokines in a dose-response manner. This inhibiting effect was sustained but not reinforced by formoterol. No synergistic effect between formoterol and budesonide was found.

In the third study, the effect of formoterol and budesonide on chemokine/cytokine release, chemokine receptor expression and chemotaxis in isolated human neutrophils in vitro was evaluated. Formoterol enhanced and budesonide inhibited IL-6, IL-8, and GRO-$\alpha$ release from LPS-stimulated neutrophils. Formoterol upregulated both CXCR1 and CXCR2 expression, whereas budesonide upregulated the expression of CXCR2 only. Despite the effects on chemokine release and drug-induced up-regulation of chemokine receptors, no influence on neutrophil chemotaxis could be demonstrated by the $\beta_2$-agonist or the glucocorticosteroid.

In the fourth study, 12 healthy subjects were exposed to organic dust in a swine barn. In this cross-over designed study, we found that one single dose of salmeterol partially protected against the increased responsiveness to methacholine. Salmeterol did not influence the inflammatory response to dust exposure. One week pre-treatment with fluticasone or ibuprofen had no effect on the airway responses and did not alter the effect of salmeterol. In addition, a retrospective analysis of pooled data from four previous studies was performed. We concluded that exposure leads to an enhancement of bronchial responsiveness to a certain maximal level which is similar in all subjects, and almost totally unrelated to pre-exposure level of bronchial responsiveness.

In conclusion, although $\beta_2$-agonists and glucocorticosteroids influence the release of pro-inflammatory cytokines/chemokines and up-regulate chemokine receptors in vitro, these drugs did not influence the investigated inflammatory parameters in vivo. As the increase in bronchial responsiveness following organic dust exposure is strongly related to pre-exposure bronchial responsiveness, interventions altering bronchial responsiveness have to be compared between groups with similar pre-challenge bronchial responsiveness or in a cross-over design. No additive/synergistic effects between $\beta_2$-agonists and steroids were found.